Candidiasis

A 5-day-old female is transferred from another hospital due to irritability and a worsening pustular rash. The mother’s pregnancy, labor and delivery was complicated by a group B strep-positive culture and vaginal candidiasis.

The FDA recently approved Rezzayo, a weekly injectable treatment for adults with candidemia and invasive candidiasis.

The FDA approved rezafungin for injection to treat candidemia and invasive candidiasis in adults, offering a new treatment for people with limited or no other options.

Nearly half of patients who received a diagnosis code of “unspecified mycosis” had positive laboratory test results for a specific fungal disease, with the most common being invasive candidiasis, researchers found.

The FDA Antimicrobial Drugs Advisory Committee voted on Wednesday 14-1 in favor of the use of rezafungin for the treatment of candidemia and invasive candidiasis.

Vulvovaginal candidiasis is a common infection that causes vaginal and vulvar irritation and itchiness, as well as discharge.

The FDA has approved Vivjoa — the first medication for recurrent vulvovaginal candidiasis — for use in permanently infertile and postmenopausal women, according to a Mycovia Pharmaceuticals press release.

The FDA this week approved Scynexis’s novel 1-day oral treatment for vulvovaginal candidiasis, ibrexafungerp, making it the first approved drug in a novel antifungal class in more than 20 years, the company said.

Ibrexafungerp was superior to placebo in patients with vulvovaginal candidiasis, with statistically significant rates of clinical cure, clinical improvement and mycological eradication, according to results of the phase 3 VANISH-306 trial.

Scynexis announced today that it has submitted a new drug application to the FDA for oral ibrexafungerp for the treatment of vulvovaginal candidiasis, the second most common cause of vaginitis.